6-K 1 a7661x.htm RESULT OF AGM a7661x
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of April 2023
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1. Result of AGM
 
 
27 April 2023 17:30 BST
 
 
 
Results of Annual General Meeting held on 27 April 2023
 
 
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
 
 
Resolution
 
Votes for
 
% of votes cast
 
Votes against
 
% of votes cast
 
Votes cast in total
 
Total votes cast as a % of issued share capital
 
Votes withheld
 
1
 
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2022
 
1,264,644,490
 
99.80
 
2,524,193
 
0.20
 
1,267,168,683
 
81.76
 
2,068,894
 
2
 
To confirm dividends
 
1,254,919,878
 
98.92
 
13,679,112
 
1.08
 
1,268,598,990
 
81.85
 
638,576
 
3
 
To reappoint PricewaterhouseCoopers LLP as Auditor
 
1,260,792,714
 
99.39
 
7,718,080
 
0.61
 
1,268,510,794
 
81.85
 
726,500
 
4
 
To authorise the Directors to agree the remuneration of the Auditor
 
1,268,225,831
 
99.98
 
270,095
 
0.02
 
1,268,495,926
 
81.85
 
741,641
 
5a
 
To re-elect Michel Demaré as a Director
 
1,241,496,328
 
97.88
 
26,829,809
 
2.12
 
1,268,326,137
 
81.84
 
911,430
 
5b
 
To re-elect Pascal Soriot as a Director
 
1,260,336,535
 
99.37
 
7,986,485
 
0.63
 
1,268,323,020
 
81.83
 
914,729
 
5c
 
To re-elect Aradhana Sarin as a Director
 
1,265,264,711
 
99.76
 
3,062,442
 
0.24
 
1,268,327,153
 
81.84
 
910,131
 
5d
 
To re-elect Philip Broadley as a Director
 
1,259,273,602
 
99.29
 
9,043,851
 
0.71
 
1,268,317,453
 
81.83
 
920,114
 
5e
 
To re-elect Euan Ashley as a Director
 
1,268,022,043
 
99.98
 
282,266
 
0.02
 
1,268,304,309
 
81.83
 
924,629
 
5f
 
To re-elect Deborah DiSanzo as a Director
 
1,267,959,577
 
99.97
 
349,778
 
0.03
 
1,268,309,355
 
81.83
 
926,746
 
5g
 
To re-elect Diana Layfield as a Director
 
1,268,027,536
 
99.98
 
274,653
 
0.02
 
1,268,302,189
 
81.83
 
935,378
 
5h
 
To re-elect Sheri McCoy as a Director
 
1,241,492,257
 
97.88
 
26,842,094
 
2.12
 
1,268,334,351
 
81.84
 
903,216
 
5i
 
To re-elect Tony Mok as a Director
 
1,261,574,735
 
99.97
 
322,367
 
0.03
 
1,261,897,102
 
81.42
 
7,338,922
 
5j
 
To re-elect Nazneen Rahman as a Director
 
1,266,284,904
 
99.85
 
1,870,104
 
0.15
 
1,268,155,008
 
81.82
 
1,082,559
 
5k
 
To re-elect Andreas Rummelt as a Director
 
1,268,030,928
 
99.98
 
285,793
 
0.02
 
1,268,316,721
 
81.83
 
920,846
 
5l
 
To re-elect Marcus Wallenberg as a Director
 
1,026,140,887
 
80.93
 
241,825,345
 
19.07
 
1,267,966,232
 
81.81
 
1,263,367
 
6
 
To approve the Annual Report on Remuneration for the year ended 31 December 2022
 
1,195,261,107
 
94.23
 
73,125,360
 
5.77
 
1,268,386,467
 
81.84
 
850,827
 
7
 
To authorise limited political donations
 
1,228,047,446
 
97.76
 
28,189,687
 
2.24
 
1,256,237,133
 
81.06
 
13,000,783
 
8
 
To authorise the Directors to allot shares
 
1,166,174,071
 
91.95
 
102,088,563
 
8.05
 
1,268,262,634
 
81.83
 
966,964
 
9
 
To authorise the Directors to disapply pre-emption rights
 
1,193,686,193
 
94.15
 
74,121,064
 
5.85
 
1,267,807,257
 
81.80
 
1,430,310
 
10
 
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
 
1,153,850,923
 
91.25
 
110,689,108
 
8.75
 
1,264,540,031
 
81.59
 
4,697,303
 
11
 
To authorise the Company to purchase its own shares
 
1,254,158,039
 
98.92
 
13,730,760
 
1.08
 
1,267,888,799
 
81.81
 
1,348,767
 
12
 
To reduce the notice period for general meetings
 
1,178,311,157
 
93.41
 
83,098,807
 
6.59
 
1,261,409,964
 
81.39
 
7,827,602
 
13
 
To adopt new Articles of Association of the Company  
 
1,258,637,857
 
99.26
 
9,327,063
 
0.74
 
1,267,964,920
 
81.81
 
1,272,646
 
 
 
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
 Issued capital
 
As at 25 April 2023, the number of issued shares of the Company was 1,549,856,584 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
 
 
AstraZeneca
 
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
 
 
Contacts
 
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
 
 
 
Adrian Kemp
Company Secretary
 
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 27 April 2023
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary